Published in Oncotarget on December 01, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle (2012) 1.41
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget (2012) 1.14
Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. PLoS One (2013) 1.12
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep (2012) 1.11
Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget (2012) 1.11
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle (2012) 1.11
Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One (2014) 1.10
Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget (2012) 1.09
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int (2014) 1.08
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Metabostemness: a new cancer hallmark. Front Oncol (2014) 1.05
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther (2013) 1.04
The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle (2012) 1.04
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis (2013) 1.04
Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One (2014) 1.04
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle (2012) 1.03
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle (2013) 1.03
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget (2013) 1.01
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle (2013) 1.00
Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle (2013) 0.99
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget (2014) 0.99
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res (2014) 0.96
The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget (2014) 0.96
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Repurposing metformin for cancer treatment: current clinical studies. Oncotarget (2016) 0.95
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget (2015) 0.94
Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities. Mediators Inflamm (2013) 0.93
Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Transl Med (2014) 0.93
Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol (2013) 0.93
IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma. Oncotarget (2014) 0.92
Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle (2013) 0.92
Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget (2015) 0.92
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget (2014) 0.91
Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget (2014) 0.91
Clinical benefits of metformin in gynecologic oncology. Oncol Lett (2015) 0.91
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine (Baltimore) (2016) 0.90
Rejuvenating regeneration: metformin activates endogenous adult stem cells. Cell Cycle (2012) 0.86
Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget (2013) 0.86
Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochem Pharmacol (2014) 0.86
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle (2014) 0.84
Autophagy, Warburg, and Warburg reverse effects in human cancer. Biomed Res Int (2014) 0.84
Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. Saudi Pharm J (2012) 0.83
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer (2014) 0.83
Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor. J Carcinog (2013) 0.83
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle (2012) 0.83
One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. Aging (Albany NY) (2012) 0.83
Metformin and the promise of geroprotection. Indian J Endocrinol Metab (2012) 0.82
Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget (2015) 0.82
The first European interdisciplinary ewing sarcoma research summit. Front Oncol (2012) 0.82
Metabolic control of cancer cell stemness: Lessons from iPS cells. Cell Cycle (2015) 0.81
Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. Int J Neuropsychopharmacol (2016) 0.81
Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget (2014) 0.81
Chemoquiescence for ideal cancer treatment and prevention: where are we now? J Cancer Prev (2014) 0.81
Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell Int (2014) 0.81
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget (2015) 0.80
Mitochondria, cholesterol and cancer cell metabolism. Clin Transl Med (2016) 0.80
L1 cell adhesion molecule expression is associated with pelvic lymph node metastasis and advanced stage in diabetic patients with endometrial cancer: a matched case control study. J Cancer Prev (2014) 0.80
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. Oncotarget (2016) 0.79
Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. Oncotarget (2015) 0.78
Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression. Cell Cycle (2015) 0.78
Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation. Mediators Inflamm (2013) 0.78
Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells. Front Oncol (2016) 0.78
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Curr Pharmacol Rep (2015) 0.78
Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. Oncotarget (2016) 0.77
The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget (2017) 0.77
Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis. Ther Adv Med Oncol (2017) 0.75
Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine. Oncotarget (2015) 0.75
Early treatment with metformin induces resistance against tumor growth in adult rats. Cancer Biol Ther (2015) 0.75
Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis. J Diabetes Res (2017) 0.75
Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. J Ovarian Res (2016) 0.75
Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients. J Cancer Sci Ther (2014) 0.75
Promising clinical practices of metformin in women with PCOS and early-stage endometrial cancer. BBA Clin (2014) 0.75
Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. PLoS One (2017) 0.75
Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer. J Turk Ger Gynecol Assoc (2016) 0.75
Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus. JAMA Ophthalmol (2015) 0.75
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells. Int J Mol Sci (2017) 0.75
Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Oncol Lett (2017) 0.75
Metformin enhances the cytotoxicity of 5-aminolevulinic acid-mediated photodynamic therapy in vitro. Oncol Lett (2017) 0.75
Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. Oncotarget (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care (1998) 18.69
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
On respiratory impairment in cancer cells. Science (1956) 14.07
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care (2008) 10.90
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 10.20
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Cellular senescence in cancer and aging. Cell (2007) 9.04
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia (2009) 7.06
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol (2004) 5.29
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
Diabetes and cancer. Endocr Relat Cancer (2009) 5.04
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev (2007) 4.91
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA (2008) 4.48
Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc (2009) 4.47
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
The common biology of cancer and ageing. Nature (2007) 4.28
Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 4.15
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer (2010) 3.95
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia (2009) 3.82
Glycolytic enzymes can modulate cellular life span. Cancer Res (2005) 3.78
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature (2007) 3.74
Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Does diabetes therapy influence the risk of cancer? Diabetologia (2009) 3.66
Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 3.60
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 3.50
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 3.34
A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 3.13
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol (2005) 3.06
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther (2010) 2.93
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Two faces of p53: aging and tumor suppression. Nucleic Acids Res (2007) 2.78
mTOR signaling and drug development in cancer. Nat Rev Clin Oncol (2010) 2.77
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia (2009) 2.60
Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) (2010) 2.60
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol (2010) 2.46
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer (2011) 2.30
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med (2008) 2.16
The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle (2009) 2.03
Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr (2011) 2.01
Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer (2006) 2.00
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.00
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (2011) 2.00
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol (2009) 1.98
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun (2010) 1.91
Obesity and prognosis of breast cancer. Obes Rev (2006) 1.91
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle (2009) 1.89
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res (2011) 1.88
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (2010) 1.85
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (2010) 1.78
Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev (2001) 1.78
Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia (2004) 1.77
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A (2004) 1.77
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle (2009) 2.03
Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol (2006) 1.99
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun (2010) 1.91
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One (2009) 1.91
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle (2009) 1.89
Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med (2008) 1.86
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (2010) 1.85
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (2010) 1.78
New variants in the mitochondrial genomes of schizophrenic patients. Eur J Hum Genet (2006) 1.72
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat (2010) 1.71
Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep (2008) 1.67
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle (2009) 1.66
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget (2012) 1.61
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle (2010) 1.60
Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol (2006) 1.58
The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci (2009) 1.57
Plasma homocysteine concentrations in patients with liver cirrhosis. Clin Chem (2002) 1.50
Dilated aortic root is related to a global aortic dilating diathesis. J Vasc Surg (2010) 1.48
Autophagy in stem cells. Autophagy (2013) 1.43
Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease. J Lab Clin Med (2002) 1.40
Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle (2012) 1.39
[Clinical applications of erythropoietin: Impact on blood transfusion]. Med Clin (Barc) (2002) 1.39
Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation (2004) 1.37
mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle (2011) 1.32
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle (2009) 1.23
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 1.20
Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) (2012) 1.20
Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem (2009) 1.20
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med (2005) 1.19
Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle (2011) 1.19
Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol Cell Biochem (2005) 1.19
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol (2014) 1.18
Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology (2006) 1.17
Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem (2003) 1.16
Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J Proteome Res (2010) 1.15
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med (2007) 1.14
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget (2012) 1.14
Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle (2012) 1.14
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol (2010) 1.14
The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep (2013) 1.14